Hexarelin: what the research shows

  • By Reed Calder
  • Last reviewed Nov 12, 2026
  • 31 studies and official documents checked

In short

Hexarelin is a lab-made six-amino-acid peptide, derived from GHRP-6, that copies the signal of the hormone ghrelin and makes the pituitary gland release growth hormone. A single injection produced a large, short surge of growth hormone in healthy men. In a 16-week study of 12 healthy older adults, though, the response to a test injection was down 45% by the end and came back 4 weeks after stopping, while IGF-1, body fat, lean mass and bone density did not change. It also raises cortisol, ACTH and prolactin, and it cut deep sleep in seven young volunteers. The heart results come from single doses and animals. It isn’t approved anywhere we found, no trial is registered, and the World Anti-Doping Agency bans it at all times.

EvidenceCellAnimalHuman

Hexarelin is sold online as a “peptide” for muscle, fat loss, recovery and anti-aging. This page covers what it is, what the human studies found over a single dose and over four months, the hormone and sleep effects, the heart data, how well it works by mouth, and where it stands legally.

Names and forms you’ll see

The names on hexarelin products
Name What it is Studied in people?
Hexarelin A lab-made peptide of six amino acids (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), derived from GHRP-6 (Mao et al., 2014) Yes: small studies
Examorelin The international nonproprietary name for hexarelin, with development codes EP-23905 and MF-6003 (PubChem) Same as hexarelin
Hexarelin acetate The salt form often sold as a powder, with a registry record of its own (PubChem). The trial reports we read don’t say which form was used Unclear
“Hexarelin peptide” A search phrase and a sales label for the same compound Same as hexarelin

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The base and the acetate salt have different registry numbers.

Hexarelin CAS numbers
Form CAS number Registry record
Hexarelin (examorelin), free base 140703-51-1 FDA GSRS
Hexarelin acetate 208251-52-9 PubChem

What hexarelin is

Ghrelin is a hormone made mainly in the stomach. It tells the pituitary gland to release growth hormone (GH). Hexarelin binds the same receptor, called GHSR-1a, and in a lab test its potency was close to ghrelin’s (half-maximal concentration 1.7 nanomoles per litre against 1.0) (Mao et al., 2014). A cardiology review calls it chemically more stable than ghrelin. In animals it also binds a second receptor, CD36, in the heart (Mao et al., 2014).

Other compounds in this group work the same way: ipamorelin, GHRP-2, GHRP-6 and the non-peptide MK-677. The growth-hormone-releasing-hormone drugs, sermorelin and tesamorelin, act on a different receptor.

Hexarelin has also been used as a lab test. A low dose (0.25 micrograms per kilogram intravenously) together with growth-hormone-releasing hormone (1 microgram per kilogram) identified adults with growth hormone deficiency about as well as the standard insulin tolerance test, in a study of 19 adults with the deficiency (Gasperi et al., 1999).

What has been studied

Growth hormone release in healthy people

  • One injection. In 12 healthy men given single intravenous injections of 0.5, 1 and 2 micrograms per kilogram, and placebo, GH rose with the dose. Peak levels were about 27, 52 and 55 ng/mL against 3.9 on placebo, at about 30 minutes, and were back to baseline within 4 hours. The top dose was close to the maximal response (Imbimbo et al., 1994).
  • Against GHRH. In 12 healthy volunteers, an intravenous dose of 1 microgram per kilogram raised GH about twice as much as the same dose of growth-hormone-releasing hormone (Ghigo et al., 1994). In six young adults, GHRP-2 and hexarelin gave similar, strong responses, both higher than the hormone’s (Arvat et al., 1997).
  • Other routes. The same study gave hexarelin under the skin (1.5 and 3 micrograms per kilogram), as a nasal spray (20 micrograms per kilogram) and by mouth (20 and 40 mg). Judged by the GH response, about 77% of a dose under the skin was effective, 4.8% as a nasal spray and 0.3% by mouth. Oral doses still raised GH in a dose-related way (Ghigo et al., 1994). Contents of the intestine break hexarelin down, and it crosses the gut wall poorly (Westberg et al., 2001).
  • Older adults, short term. Seven people aged 67 to 80 took 1.25 mg as a nasal spray three times a day for 8 days, and seven women aged 63 to 80 took 20 mg by mouth three times a day for 15 days. Their GH response was maintained. IGF-1 didn’t change significantly with the nasal spray and was slightly higher by mouth (156.0 vs 141.6 micrograms per litre) (Ghigo et al., 1996).
  • Body fat matters. In 21 healthy older adults, the GH response to a single injection under the skin (1.5 micrograms per kilogram) was lower in people with more body fat (correlation −0.72 with fat mass) (Rahim et al., 1998).
  • Food. In six men and six women aged 23 to 29, a meal partly blunted the GH response to hexarelin (by 41% on average) and nearly abolished the response to growth-hormone-releasing hormone (by 70%) (De Marinis et al., 2000).
  • Kidney failure. In six young dialysis patients, 1 and 2 micrograms per kilogram intravenously raised GH, and 2 was the most effective dose. ACTH and cortisol rose in all groups, and the GH response tended to be lower with age (Jenkins et al., 1999).
  • No GHRH signal, no response. Four men with a mutation in the receptor for growth-hormone-releasing hormone had no GH response to 2 micrograms per kilogram, though their prolactin, ACTH and cortisol rose normally. Hexarelin needs that signalling to release GH (Maheshwari et al., 1999).

Longer use

  • 16 weeks. In 12 healthy older adults on injections under the skin twice a day (1.5 micrograms per kilogram), the GH response to a test injection fell from 19.1 to 13.1 at week 1 (31% lower), 12.3 at week 4 (36%) and 10.5 at week 16 (45%), in micrograms per litre-hour. Four weeks after stopping it was 19.4, back to baseline (Rahim et al., 1998; Rahim et al., 1998).
  • What didn’t change. In the same study IGF-1, IGF binding protein 3, total body fat, lean body mass and bone density did not change significantly. One bone-formation marker rose (Rahim et al., 1998).
  • Cortisol response. The cortisol response to an injection fell by week 16 and returned 4 weeks after stopping. Basal cortisol and urinary free cortisol did not change (Rahim et al., 1999).
  • Within a day. In six young men, two or three injections of 1.5 micrograms per kilogram in 24 hours raised 24-hour GH equally and did not change IGF-1. An intravenous test dose of 1 microgram per kilogram at the end of the day produced a blunted GH response and no ACTH or cortisol response (Maccario et al., 2002).

Other hormones and sleep

  • Stress hormones. In 15 healthy young men, hexarelin raised ACTH and cortisol, apparently through vasopressin and not through CRH, and caused a small, brief rise in appetite (Korbonits et al., 1999). In six young adults it raised prolactin, ACTH and cortisol much as GHRP-2 did (Arvat et al., 1997).
  • Sleep. In seven young volunteers given four injections of 50 micrograms, at 10 pm, 11 pm, midnight and 1 am, deep (stage 4) sleep and delta brain-wave power fell. GH and prolactin rose through the night, and ACTH and cortisol rose in the first half. The authors suggested sleep is impaired (Frieboes et al., 2004).

Children and heart patients

  • Short children. Eight prepubertal children took a nasal spray, 60 micrograms per kilogram three times a day, for up to 8 months. IGF-1 rose from 10.4 to 14.1 nanomoles per litre, and growth rate rose from 5.3 to 8.3 cm a year. The authors report no undesirable side effects. No control group was described (Laron et al., 1995).
  • A single dose and the heart. In seven men, an intravenous dose raised the fraction of blood the heart pumps out with each beat (ejection fraction) from 64.0% to 70.7% without changing blood pressure or heart rate. Recombinant GH, which raised GH to the same level, did not (Bisi et al., 1999). In 24 men with coronary artery disease having bypass surgery, one dose raised ejection fraction and cardiac output, lowered wedge pressure and raised mean blood pressure (Broglio et al., 2002). In five people with severe ischaemic cardiomyopathy it rose from 22.6% to 26.2%, and in eight with dilated cardiomyopathy it did not change (Imazio et al., 2002).
  • The review. A 2014 review of the heart evidence lists human studies that were all acute intravenous doses, 2 micrograms per kilogram in each. The longer-term findings, such as less scarring, fewer clogged arteries and smaller heart-attack damage, were in rats, mice and cell lines. The authors call for clinical trials (Mao et al., 2014).

Animals

  • Mice. In non-obese, insulin-resistant mice given twice-daily injections of 200 micrograms per kilogram for 12 days, hexarelin improved glucose handling and lowered blood and liver triglycerides. Fat mass fell and lean mass rose. Food intake rose and body weight did not change (Mosa et al., 2017).
  • Overview. A 2026 review says the body-composition evidence for hexarelin in people is limited and does not come from controlled trials built to test it (Dominikowski et al., 2026).

EvidenceCellAnimalHuman

The usual claims, checked

Common hexarelin claims vs the studies
Claim Verdict What the studies found
It boosts growth hormone a lot Mixed True for a single injection: peaks of 27 to 55 ng/mL against 3.9 on placebo (Imbimbo et al., 1994). With repeated use the response shrank by 31% at week 1 and 45% at week 16 (Rahim et al., 1998)
It raises IGF-1 and builds muscle Contradicted IGF-1 and lean mass did not change over 16 weeks in older adults (Rahim et al., 1998). Eight children on a nasal spray had higher IGF-1 in an uncontrolled report (Laron et al., 1995). A 2026 review calls the body-composition evidence limited (Dominikowski et al., 2026)
It burns fat Contradicted Total body fat did not change over 16 weeks in older adults (Rahim et al., 1998). Fat mass fell in insulin-resistant mice (Mosa et al., 2017)
It protects or repairs the heart Mixed Single intravenous doses raised the heart’s ejection fraction in volunteers, surgery patients and people with ischaemic cardiomyopathy, but not dilated cardiomyopathy (Bisi et al., 1999; Imazio et al., 2002). The repair findings are from animals and cells (Mao et al., 2014)
It is orally active Mixed About 0.3% of an oral dose was effective by the GH response (Ghigo et al., 1994), and gut contents break it down (Westberg et al., 2001). Oral doses did raise GH in older women over 15 days (Ghigo et al., 1996)
It has no side effects Contradicted It raised cortisol, ACTH and prolactin (Korbonits et al., 1999; Arvat et al., 1997) and cut deep sleep in seven young volunteers (Frieboes et al., 2004). We found no adult study longer than 16 weeks
You can avoid the fall in response by cycling it Untested The one long study used continuous twice-daily injections for 16 weeks, and the response recovered 4 weeks after stopping (Rahim et al., 1998). We found no study that tested an on-and-off schedule
It beats ipamorelin, sermorelin or tesamorelin Untested No trial compared them. Hexarelin raised cortisol and prolactin in people (Arvat et al., 1997); see ipamorelin, sermorelin and tesamorelin for what each shows
It is a proven anti-aging treatment Untested We found no trial measuring an aging outcome. The 16-week trial in older adults found no change in body composition or IGF-1 (Rahim et al., 1998)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

Side effects and safety

  • Stress hormones. Cortisol, ACTH and prolactin rose after injections (Korbonits et al., 1999; Arvat et al., 1997). Over 16 weeks the cortisol response to an injection fell, while basal cortisol and urinary free cortisol did not change (Rahim et al., 1999).
  • Sleep. Less deep sleep and lower delta power in seven young volunteers (Frieboes et al., 2004).
  • Appetite. A small, brief rise in appetite in 15 men (Korbonits et al., 1999).
  • Blood pressure. Unchanged in seven volunteers (Bisi et al., 1999), but mean blood pressure rose in 24 surgery patients (Broglio et al., 2002).
  • What the FDA says about its relatives. For GHRP-2, the FDA cites immunogenicity risk from aggregation and impurities, and reports of serious events including a higher insulin requirement, infection and pancreatitis, with causality not established. For GHRP-6 it cites an effect on cortisol and a rise in blood sugar (FDA, 2026). Hexarelin has no entry on that page.
  • Small studies. Most trials enrolled a handful of men, seven to fifteen older adults, or eight children. We found none longer than 16 weeks apart from the children’s report, and no analysis of the contents of hexarelin sold online.

Legal and approval status

  • No approved product. Drugs@FDA lists no hexarelin or examorelin product (openFDA search, no match), and ClinicalTrials.gov lists no study of either name (ClinicalTrials.gov search).
  • Not on the FDA’s compounding lists, unlike its relatives. Hexarelin has no entry on the FDA’s safety-risk page (FDA, 2026) or in its May 2026 compounding categories (FDA list, May 2026). GHRP-2 and GHRP-6 are on both the safety-risk page and the category 3 list. Absence from the lists isn’t approval.
  • Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
  • Banned in sport at all times. The World Anti-Doping Agency’s 2026 list names “examorelin (hexarelin)” under S2, prohibited in and out of competition (WADA, 2026).
  • “Research use only” products aren’t approved for use in people.

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and registries:

  • Which form? The base is CAS 140703-51-1 and the acetate is 208251-52-9 (FDA GSRS; PubChem). The trials we read don’t say which was used.
  • Route. Most of the human data are from injections. A page selling a nasal spray or capsule should explain the 4.8% and 0.3% figures (Ghigo et al., 1994).
  • Heart claims. A page quoting heart benefits should say they were single intravenous doses in small groups or animal studies (Mao et al., 2014).
  • “Peptide stacks.” No study we found combined hexarelin with other secretagogues for weeks or months in people.

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite. For other compounds in this group, see growth hormone secretagogues.

What’s still unknown

  • Safety and effects beyond 16 weeks in adults.
  • Whether any schedule limits the fall in growth hormone response.
  • Whether repeated use helps the heart, since human heart data are single doses.
  • Effects in women and in younger adults over weeks or months.
  • What is in the vials and capsules sold online, and whether the form matches the studies.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Hexarelin. We recheck every month. Last checked Nov 12, 2026.

We found no retracted, withdrawn or flagged studies that mention Hexarelin.

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Imbimbo et al., 1994 Eur J Clin Pharmacol No retraction or concern
Ghigo et al., 1994 J Clin Endocrinol Metab No retraction or concern
Laron et al., 1995 Clin Endocrinol (Oxf) No retraction or concern
Ghigo et al., 1996 Eur J Endocrinol No retraction or concern
Arvat et al., 1997 Peptides No retraction or concern
Rahim et al., 1998 J Clin Endocrinol Metab No retraction or concern
Maheshwari et al., 1999 J Clin Endocrinol Metab No retraction or concern
Rahim et al., 1998 Clin Endocrinol (Oxf) No retraction or concern
Jenkins et al., 1999 J Clin Endocrinol Metab No retraction or concern
Rahim et al., 1999 Clin Endocrinol (Oxf) No retraction or concern
Bisi et al., 1999 J Endocrinol Invest No retraction or concern
Korbonits et al., 1999 J Clin Endocrinol Metab No retraction or concern
Gasperi et al., 1999 J Clin Endocrinol Metab No retraction or concern
De Marinis et al., 2000 Horm Metab Res No retraction or concern
Rahim and Shalet, 1998 Growth Horm IGF Res No retraction or concern
Westberg et al., 2001 J Pharm Pharmacol No retraction or concern
Maccario et al., 2002 Eur J Endocrinol No retraction or concern
Imazio et al., 2002 Eur J Heart Fail No retraction or concern
Broglio et al., 2002 Eur J Pharmacol No retraction or concern
Frieboes et al., 2004 Psychoneuroendocrinology No retraction or concern
Mao et al., 2014 J Geriatr Cardiol No retraction or concern
Mosa et al., 2017 Endocrinology No retraction or concern
Dominikowski et al., 2026 Front Endocrinol (Lausanne) No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is hexarelin?

A lab-made peptide of six amino acids that binds the ghrelin receptor and makes the pituitary release growth hormone (Mao et al., 2014). It is not approved anywhere we found.

Is hexarelin the same as GHRP-6 or GHRP-2?

It was derived from GHRP-6 (Mao et al., 2014). In six young adults, GHRP-2 and hexarelin gave similar GH responses (Arvat et al., 1997).

What does hexarelin do?

It makes a short, large rise in growth hormone and also raises cortisol, ACTH and prolactin (Imbimbo et al., 1994; Korbonits et al., 1999).

Does hexarelin increase muscle mass?

Not in the one long study: lean mass did not change over 16 weeks in older adults (Rahim et al., 1998).

Does hexarelin burn fat?

Total body fat did not change in older adults over 16 weeks (Rahim et al., 1998). Fat mass fell in mice (Mosa et al., 2017).

How long does it take to see results from hexarelin?

No study measured visible results. What it did show is that the growth hormone response fell by about a third within a week of twice-daily injections (Rahim et al., 1998).

Is hexarelin better than ipamorelin?

No trial compared them. Hexarelin raised cortisol and prolactin in people (Arvat et al., 1997). See ipamorelin for its evidence.

Is hexarelin better than sermorelin?

No trial compared them. They act on different receptors. See sermorelin.

Hexarelin vs tesamorelin: which is better?

No trial compared them. Tesamorelin is FDA-approved for belly fat in HIV, and hexarelin is not approved.

What are the side effects of hexarelin?

Higher cortisol, ACTH and prolactin, less deep sleep and a small rise in appetite in small studies (Frieboes et al., 2004; Korbonits et al., 1999).

Is hexarelin safe?

We don’t know long term. The longest study we found ran 16 weeks in 12 people (Rahim et al., 1998), and the FDA flags concerns about GHRP-2 and GHRP-6 (FDA, 2026).

Is hexarelin FDA approved or legal?

It is not approved. Drugs@FDA lists no product, and no trial is registered (openFDA search, no match; ClinicalTrials.gov search). Our guide to what to look for covers the routes people use.

Is hexarelin banned in sports?

Yes. The World Anti-Doping Agency lists “examorelin (hexarelin)” as prohibited at all times (WADA, 2026).

Does hexarelin work by mouth or as a nasal spray?

Poorly compared with injection: about 4.8% nasally and 0.3% orally by the GH response (Ghigo et al., 1994). It was still active in older adults over days (Ghigo et al., 1996).

What is the hexarelin half-life?

We found no reliable human half-life. After an intravenous dose, growth hormone peaked at about 30 minutes and was back to baseline within 4 hours (Imbimbo et al., 1994).

What is the hexarelin dosage?

Studies gave 0.5 to 2 micrograms per kilogram intravenously, 1.5 to 3 micrograms per kilogram under the skin as single doses, 1.5 micrograms per kilogram twice a day for 16 weeks, 20 micrograms per kilogram as a nasal spray, and 20 to 40 mg by mouth (Imbimbo et al., 1994; Ghigo et al., 1994; Rahim et al., 1998). No study has set a dose for use outside a trial, and we don’t give dosing advice.

Sources

  1. Imbimbo BP, et al. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. 1994;46(5):421-5. PubMed 7957536
  2. Ghigo E, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab. 1994;78(3):693-8. PubMed 8126144
  3. Ghigo E, et al. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol. 1996;135(4):407-12. PubMed 8921821
  4. Rahim A, et al. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab. 1998;83(5):1644-9. PubMed 9589671
  5. Rahim A, et al. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-3. PubMed 10990150
  6. Rahim A, et al. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin Endocrinol (Oxf). 1999;50(1):77-84. PubMed 10341859
  7. Rahim A, et al. The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects. Clin Endocrinol (Oxf). 1998;49(5):659-64. PubMed 10197083
  8. Maccario M, et al. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Eur J Endocrinol. 2002;146(3):310-8. PubMed 11888836
  9. Frieboes RM, et al. Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology. 2004;29(7):851-60. PubMed 15177700
  10. De Marinis L, et al. Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects. Horm Metab Res. 2000;32(4):152-6. PubMed 10824712
  11. Jenkins RC, et al. The effects of dose, nutrition, and age on hexarelin-induced anterior pituitary hormone secretion in adult patients on maintenance hemodialysis. J Clin Endocrinol Metab. 1999;84(4):1220-5. PubMed 10199757
  12. Maheshwari HG, et al. Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency. J Clin Endocrinol Metab. 1999;84(3):956-9. PubMed 10084578
  13. Korbonits M, et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab. 1999;84(7):2489-95. PubMed 10404825
  14. Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-91. PubMed 9285939
  15. Bisi G, et al. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest. 1999;22(4):266-72. PubMed 10342360
  16. Broglio F, et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. Eur J Pharmacol. 2002;448(2-3):193-200. PubMed 12144941
  17. Imazio M, et al. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. Eur J Heart Fail. 2002;4(2):185-91. PubMed 11959048
  18. Laron Z, et al. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf). 1995;43(5):631-5. PubMed 8548949
  19. Gasperi M, et al. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test. J Clin Endocrinol Metab. 1999;84(8):2633-7. PubMed 10443652
  20. Westberg C, et al. Hexarelin--evaluation of factors influencing oral bioavailability and ways to improve absorption. J Pharm Pharmacol. 2001;53(9):1257-64. PubMed 11578108
  21. Mao Y, et al. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014;11(3):253-8. PubMed 25278975
  22. Mosa R, et al. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. Endocrinology. 2017;158(10):3174-3187. PubMed 28977588
  23. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176
  24. ClinicalTrials.gov. Searches for hexarelin and examorelin, November 12, 2026: no studies. Search
  25. U.S. Food and Drug Administration. Drugs@FDA data via openFDA, searched November 12, 2026: no hexarelin or examorelin product or label. openFDA search, no match
  26. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  27. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
  28. World Anti-Doping Agency. 2026 Prohibited List, section S2.2.4. WADA document
  29. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  30. U.S. Food and Drug Administration. Global Substance Registration System: EXAMORELIN (UNII 09QF37C617). GSRS
  31. National Library of Medicine. PubChem compound record: Hexarelin acetate (CID 88325556). PubChem

Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.